A Pilot Study of the Provant Therapy System in Subjects With Diabetic Foot Ulcers
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00761176|
Recruitment Status : Terminated (Protocol Violations noted for 6 of 8 patients)
First Posted : September 29, 2008
Results First Posted : January 5, 2016
Last Update Posted : January 5, 2016
|Condition or disease||Intervention/treatment|
|Diabetic Foot Ulcers||Device: The Provant Therapy System|
According to the American Diabetes Association (ADA), there are approximately 20.8 million people in the US with diabetes or 7% of the population (1). A significant number of the diabetic population is prone to pedal ulceration and estimates reveal that 15-20% of this population will develop a foot ulcer in their lifetime.
Treatment of diabetic foot ulcerations have posed a problem to healthcare providers for many years. The literature describes many different modalities for direct wound treatment strategies. Most of these treatments rely on the timely application of biological dressings, offloading of the wound, regular (and often inconvenient) visits to the doctor, and most important, compliance by the patient. It is not uncommon for such wounds to be present for greater than six months, despite use of debridement, off-loading and other basic wound care techniques, before presenting for advanced therapy.
Provant has been selected for study because:
- It is already indicated for the adjunctive palliative treatment of postoperative pain and edema in superficial soft tissue.
- It is a non-invasive wound treatment system which utilizes a proprietary PRFE signal which is hypothesized to trigger the release of endogenous growth factors that induce mitosis through accelerating the cell cycle, using a Ca+2 mediated pathway. The result is a significant increase in the rate of cell replication.
- It has also been shown that PRFE triggers a genetic sequence or cascade of 'wound repair' genes critical for the four stages of wound healing: inflammation, granulation, epithelialization, and remodeling.
- It has been utilized in the VA Health System since 2004 with no serious adverse events attributable to the device.
This study will assess as an endpoints:
- Primary - the incidence of wounds reaching complete closure, and
- Secondary - the time to complete wound closure percentage reduction in wound area, percentage reduction in wound volume, and rate of healing mm2/day and mm3/day.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||8 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Controlled Study Comparing Basic Wound Care to the Provant® Therapy System as an Adjunct to Basic Wound Care for Wound Surface Area Reduction in Diabetic Plantar Foot Wounds|
|Study Start Date :||July 2008|
|Primary Completion Date :||March 2011|
|Study Completion Date :||March 2011|
No Intervention: Standard of Care
Standard of Care will be utilized without the device.
The Provant Therapy System
Thirty minutes, twice daily treatment
Device: The Provant Therapy System
The Provant Wound Therapy System is a safe adjuvant non-invasive medical device.
Other Name: Radio frequency generator devices
- The Incidence of Wounds Reaching Complete Closure [ Time Frame: approximate one year ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00761176
|United States, North Carolina|
|Winston - Salem Outpatient Clinic|
|Winston - Salem, North Carolina, United States, 27103|
|Principal Investigator:||Mike Wilson, DPM||Winston - Salem Outpatient Clinic, WG Hefner VAMC|